STARTUP PROFILE

Synchron

COUNTRY

USA

FOUNDED

2016

CATEGORY

Brain-Computer Interface

Developing the Stentrode, an endovascular, minimally invasive BCI implant enabling paralyzed individuals to control digital devices using thought alone.

Visit website →

← Back to Startups

•

Neurofounders Insights

$ Funding -

Series C+

MODALITY

Endovascular

FORM FACTOR

Implant

INTERFACE DEPTH

Minimally invasive

INDICATION

Paralysis/motor

TARGET USER

Patients

REGULATORY STAGE

Investigational

Synchron is the leading endovascular BCI company, differentiated by the Stentrode’s ability to reach the brain without open-skull surgery. This minimally invasive route gives it one of the clearest practical advantages in the assistive BCI field, even if bandwidth is lower than intracortical systems.

Related companies

Precision Neuroscience

INBRAIN Neuroelectronics

Blackrock Neurotech

•

Mentioned in Market Notes

MOST RECENT COVERAGE

No items found.

Articles featuring

Synchron

How Many People Live With An Implanted BCI Today?

Implanted BCIs are shifting from first-in-human cases to repeat use. But how many people live with chronic implants, and where do commercial and academic programs diverge?

How Does Synchron's Brain-Computer Interface Work?

Synchron’s endovascular BCI prioritizes deployability over maximal signal fidelity. The system is engineered around existing clinical infrastructure, reshaping how scalability, risk, and utility are balanced.

Ten BCI Companies Now in Human Trials

Brain-computer interfaces are entering regulated human trials across invasive, minimally invasive, and non-invasive approaches, signalling a shift from experimental demos to real clinical pipelines.

The Big 6 of BCI: Where Neurotech Funding Is Flowing

Capital is concentrating around six invasive BCI leaders as investors back platforms with repeatable surgery, stable signals, and clear regulatory paths. The field is shifting from proof-of-concept to execution.